Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800mg after progression on 400mg
- 31 August 2005
- journal article
- clinical trial
- Published by Elsevier BV in European Journal of Cancer
- Vol. 41 (12), 1751-1757
- https://doi.org/10.1016/j.ejca.2005.04.034
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Imatinib pharmacokinetics in patients with gastrointestinal stromal tumour: a retrospective population pharmacokinetic study over time. EORTC Soft Tissue and Bone Sarcoma GroupCancer Chemotherapy and Pharmacology, 2004
- Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trialThe Lancet, 2004
- Current clinical management of gastrointestinal stromal tumorsExpert Review of Anticancer Therapy, 2004
- Gastrointestinal Stromal Tumors Respond to Tyrosine Kinase-targeted Therapy.Current Treatment Options in Gastroenterology, 2004
- Efficacy and Safety of Imatinib Mesylate in Advanced Gastrointestinal Stromal TumorsThe New England Journal of Medicine, 2002
- Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I studyThe Lancet, 2001
- Phase II Clinical Trial Design for Noncytotoxic Anticancer Agents for Which Time to Disease Progression Is the Primary EndpointControlled Clinical Trials, 2000
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000